Reactivation of the silenced BASP1 gene suppresses oncogenic WNT signaling in human colorectal cancer cells
Authors:
- Leonie I. WeberLWLeonie I. Weber
- Lea E. TimpenLTLea E. Timpen
- Anna-Sophia Egger-HörschingerAEAnna-Sophia Egger-Hörschinger
- Nesin D. AyhanNANesin D. Ayhan
- David DemmelDDDavid Demmel
- Madlen HotzeMHMadlen Hotze
- Mahdi MehrabiMMMahdi Mehrabi
- Eduard StefanESEduard Stefan
- Nassim Ghaffari-Tabrizi-WizsyNGNassim Ghaffari-Tabrizi-Wizsy
Open Access
- 5 March 2026
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (10)
Abstract
Starting from human colon cancer cells showing aberrant WNT/β-catenin/TCF signaling, hyperactivated MYC, and silenced BASP1 , we generated stable cell lines overexpressing BASP1 , either ectopically, or by reactivating the dormant BASP1 promoter using a lentiviral CRISPR-based system. BASP1 encodes a neuronal signaling protein and transcriptional corepressor, from which tumor-suppressive functions have been described in avian cell systems and in multiple human cancer cell types. Proteome and transcriptome analyses revealed activation of several tumor and metastasis suppressors in BASP1-expressing cells, which also show strong repression of the transformed phenotype in terms of contact inhibition, anchorage-independent growth, and tumor formation. Cells with reactivated BASP1 display a flat and differentiated morphology with enhanced migratory potential, accompanied by expression of multiple genes implicated in actin polymerization, focal adhesion, and neuronal migration. Furthermore, MYC protein expression is substantially repressed due to BASP1-mediated transcriptional MYC downregulation involving BASP1 interaction with β-catenin and binding to the MYC promoter. Upon BASP1 activation, multiple key proteins of the canonical WNT signaling pathway become suppressed. One of these BASP1 targets is the protein kinase TNIK catalyzing phosphorylation of TCF7L2, the latter required for transcriptional MYC activation. Results obtained with a preclinical TNIK inhibitor in human colorectal cancer cells show efficient abrogation of MYC expression and consequently impaired dimerization with its interaction partner MAX. The antagonistic BASP1 effect on MYC and the MYC dependency on TNIK could enhance the development of strategies to interfere with oncogenic functions of the cancer driver MYC.Keywords
Funding Information
- Austrian Science Fund (P33662)
This publication has 96 references indexed in Scilit:
- Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoproteinProceedings of the National Academy of Sciences, 2005
- Wnt signalling in stem cells and cancerNature, 2005
- BASP1 Is a Transcriptional Cosuppressor for the Wilms' Tumor Suppressor Protein WT1Molecular and Cellular Biology, 2004
- AP-1: a double-edged sword in tumorigenesisNature Reviews Cancer, 2003
- Metastasis Suppressor Genes: Basic Biology and Potential Clinical UseClinical Breast Cancer, 2003
- JAC , a direct target of oncogenic transcription factor Jun, is involved in cell transformation and tumorigenesisProceedings of the National Academy of Sciences, 2001
- Assignment1 of brain acid-soluble protein 1 (BASP1) to human chromosome 5p15.1→p14, differential expression in human cancer cell lines as a result of alterations in gene dosageCytogenetic and Genome Research, 2000
- Shared and Unique Roles of Cap23 and Gap43 in Actin Regulation, Neurite Outgrowth, and Anatomical PlasticityJournal of Cell Biology, 2000
- β-Catenin regulates expression of cyclin D1 in colon carcinoma cellsNature, 1999
- Identification of c- MYC as a Target of the APC PathwayScience, 1998